MTAP and nasopharyngeal carcinoma: In vivo, FIDAS-5 elicited marked antitumor activity in an MTAP-deficient NPC PDX, Xeno-76 while no such antitumor effect was observed for MTAP-WT C666-1 tumors (Fig. 7G, H).